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This review concentrates on tumours that are anatomically localised in head and neck regions. Brain cancers and
head and neck cancers together account for more than 873,000 cases annually worldwide, with an increasing
incidence each year. With poor survival rates at late stages, brain and head and neck cancers represent serious
conditions. Carcinogenesis is a multi-step process and the role of infectious agents in this progression has not been
fully identified. A major problem with such research is that the role of many infectious agents may be
underestimated due to the lack of or inconsistency in experimental data obtained globally. In the case of brain
cancer, no infection has been accepted as directly oncogenic, although a number of viruses and parasites are
associated with the malignancy. Our analysis of the literature showed the presence of human cytomegalovirus
(HCMV) in distinct types of brain tumour, namely glioblastoma multiforme (GBM) and medulloblastoma. In
particular, there are reports of viral protein in up to 100% of GBM specimens. Several epidemiological studies
reported associations of brain cancer and toxoplasmosis seropositivity. In head and neck cancers, there is a distinct
correlation between Epstein-Barr virus (EBV) and nasopharyngeal carcinoma (NPC). Considering that almost every
undifferentiated NPC is EBV-positive, virus titer levels can be measured to screen high-risk populations. In addition
there is an apparent association between human papilloma virus (HPV) and head and neck squamous cell
carcinoma (HNSCC); specifically, 26% of HNSCCs are positive for HPV. HPV type 16 was the most common type
detected in HNSCCs (90%) and its dominance is even greater than that reported in cervical carcinoma. Although
there are many studies showing an association of infectious agents with cancer, with various levels of involvement
and either a direct or indirect causative effect, there is a scarcity of articles covering the role of infection in
carcinogenesis of brain and head and neck cancers. We review recent studies on the infectious origin of these
cancers and present our current understanding of carcinogenic mechanisms, thereby providing possible novel
approaches to cancer treatment.
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More than 237,000 people are diagnosed with brain can-
cer annually [1]. Central nervous system (CNS) tumours
are classified by the World Health Organization according
to histological pattern, cell behaviour, and cytogenetics. A
significant proportion is neuroepithelial tumours, which
include glial and non-glial tumours. Classification add-
itionally includes tumours in the meninges (meningioma);
germ cell tumours; tumours of the sellar region, CNS* Correspondence: akakpenova@nu.edu.kz
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reproduction in any medium, provided the orlymphatic tissue, and peripheral nerves; and metastatic
tumours. Histological features and malignancy of the
tumour are graded from Grade I to Grade IV for uniform-
ity and prognostic purposes [2].
Each year, 500,000 new head and neck cancer cases
are diagnosed worldwide [3]. The classification of these
tumours is based mostly on histological and clinical
findings [4,5]. Most head and neck cancers are squa-
mous cell carcinomas progressing from the thin epithe-
lial lining of the head and neck tissue.
Although many potential risk factors for brain and
head and neck cancers have been identified, including
smoking and chewing tobacco, alcohol consumption,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reflux disease, haematopoetic stem cell transplantation,
ionising radiation, electromagnetic fields, and exposure
to carcinogenic chemicals, various pathogenic infections
also constitute an under-appreciated but significant risk
[6,7]. The International Agency for Research on Cancer
(IARC) estimated that 16% of total new cancer cases and
20% of deaths from cancer worldwide in 2008 were due
to infections. Infectious agents are thought to cause vari-
ous pathological alterations including DNA mutations,
cell cycle modulation, dysregulation of DNA repair
mechanisms, chronic inflammation, and immune system
impairment [8-13]. Therefore, treating such conditions
and their cause (i.e., infections) may interfere with car-
cinogenesis or even prevent cancer. This approach has
been approved worldwide for Helicobacter pylori, hepa-
titis B and C viruses, and human papillomaviruses, and
shown to prevent corresponding cancers such as gastric,
liver, and cervical cancer. This review concentrates on
recent updates on brain and head and neck oncological
diseases, which are combined for analysis due to their
common localisation in the head region. These cancers
are also associated with a number of pathogens although
it is not yet clear whether the infectious agents actually
cause the cancer or act as co-factors or bystanders. So, the
mechanisms underlying precancerous conditions and car-
cinogenesis associated with infections will be discussed.
Brain cancer
Brain cancers include tumours located within the brain
and CNS. Among neuroepithelial tumours, the most fre-
quent (50-60%) is glioblastoma. Glioblastoma multi-
forme (GBM) is highly anaplastic and develops from a
diffuse astrocytoma or de novo [2]. GBM is often found
in the cerebral hemispheres and its peak incidence
occurs at an age of 45–70 years. Some tumours occur
more frequently in children, such as medulloblastoma,
brain stem glioma, ependydoma, and pineal tumour.
Medulloblastoma is often found in the cerebellum and
can spread to other CNS regions. Histopathology indi-
cates that medulloblastoma originates from primitive
undeveloped cells. Some brain tumours can be benign,
such as meningiomas arising from membranes of the
brain and CNS [2].
Glioblastoma and cytomegalovirus
The role of human cytomegalovirus (HCMV) in the
pathogenicity of glial tumours is attracting increasing
interest. CMV DNA or antigen levels are elevated in
many cancer types, and CMV is directly detected at a
high frequency in brain cancers. Using highly sensitive
detection techniques such as immunohistochemical de-
tection and PCR amplification, HCMV nucleic acids and
genes were found in >90-95% of GBM tumours [14] andCMV proteins pp65 or IE1 were detected in approxi-
mately 50% of GBMs [15]. Markedly, the expression of
IE1, pp65, and late antigens was detected in 100% of 27
GBM specimens, but not within surrounding brain tissue
or other brain pathology specimens [16-19]. However, in a
different study no circulating CMV was detected in per-
ipheral blood of five GBM patients, possibly due to a sub-
type difference [20]. Moreover, it should be noted that
glioblastoma incidence and cytomegalovirus seropositivity
differs among ethnic groups [21].
Medulloblastoma and cytomegalovirus
HCMV proteins were also detected in human medullo-
blastoma cell lines, accounting for as much as 92% of
immediate early protein and 73% of late protein. In
addition, a high level of CMV DNA and viral protein
was identified in primary medulloblastoma, medulloblas-
toma cell lines, and xenografts [22]. Together, these
findings from cell or tissue culture and patient blood
analysis indicate a role of CMV in various types of brain
cancer. However, further research on the underlying
mechanisms is needed, as discussed further.
Glial tumours, medulloblastoma, CNS tumours, and
polyomaviruses
Brain cancer is commonly associated with polyoma-
viruses such as SV40, BKV, and JCV [23]. Association of
SV40 with the development of brain tumours was first
noticed in infected scientists who had worked with virus
cultures [24]. Direct induction of SV40 oncogenesis was
subsequently experimentally proved in many murine
models [25]. Although some papers have reported BKV-
associated central nervous system tumours [26,27], con-
flicting reports show no association [28]. Expression of
JCV proteins and nucleic acids was detected in several
cases of glial tumours, medulloblastoma, and lymph-
omas that localised to the nervous system. JCV infection
can cause neurodegenerative abnormalities in the central
nervous system (CNS), for example progressive multi-
focal leukoencephalopathy, which can be lethal [9].
Mechanisms that are common to all polyomaviruses are
discussed further.
Brain cancer and intracellular parasites
Association of brain cancers and neurocysticercosis with
infection has been reported in several reviews [29,30]
and is under continued investigation. Certain geograph-
ical associations have provoked interest in further re-
search on this topic. Recent work by Thomas et al.
(2011) showed that the incidence of brain tumours is
higher in geographic regions where the protozoan para-
site Toxoplasma gondii is common [31]. Another study
revealed that brain cancer mortality increased with
increased T. gondii seroprevalence in France [7]. Direct
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gondi infection caused glioma. Regarding human speci-
mens, T. gondi antibodies were found in astrocytoma
[32] and meningioma [33] samples. Such associations
and the direct presence of infectious particles in brain
tumours warrant further research at the molecular level
into the role of parasitic infection in carcinogenesis or
the creation of a precancerous environment.
Brain cancer and bacteria
Interestingly, there is not much information on the asso-
ciation of brain cancer with bacterial infection. Myco-
plasma infections have been found in different types of
carcinoma tissue, including glioma [34], however such
infections are more commonly associated with cytokine-
mediated damage and inflammatory lesions [35] leading
to various CNS diseases [36]. Although one study
reported that 5 of 20 medulloblastoma tumours con-
tained Brucella DNA identified by the OMP31 primer/
probe set, the association of neurobrucellosis with
medulloblastoma remains uncertain and needs further
study [37]. At the present time the low numbers do not
support the association and the authors suspect that the
DNA came from the diet rather than from infections.
Although some bacterial species are suspected to be
present in carcinoma tissues, there is currently insuffi-
cient information to conclude that bacteria play any role
in brain cancer.
Head and neck cancers
Biologically, head and neck cancer refers to the group of
cancers located in the aerodigestive tract including lip,
oral cavity, nasal cavity, paranasal sinuses, pharynx and
larynx, oropharynx and hypopharynx, as well as the sal-
ivary glands and local lymph nodes. Most cases of head
and neck cancer (approximately 90%) are squamous cell
carcinomas. Head and neck squamous cell carcinoma
(HNSCC) is derived from the mucosal lining throughout
the local region, inducing tumour development in the
nasal and oral cavities, nasopharynx, larynx, oropharynx,
hypopharynx, and paranasal sinuses.
Nasopharyngeal carcinoma and EBV
Epstein-Barr virus (EBV) has classically been associated
with nasopharyngeal carcinoma (NPC), Burkitt’s lymph-
oma, and Hodgkin’s lymphoma and, to lesser extent,
HIV-positive CNS lymphomas and hypopharyngeal and
laryngeal tumours [38]. NPC is a head and neck cancer
that occurs endemically in some countries of the Medi-
terranean region and Asia, where EBV antibody titers
can be measured to screen high-risk populations. It is
also a leading cancer of the epithelial cell lining, and is
responsible for nasopharyngeal neoplasms that are com-
mon in adolescents and children. All types of NPC occurtwice as frequently in males than in females, and type 2
and 3 carcinomas are associated with EBV virus titre
levels [39,40]. Almost every undifferentiated NPC is
EBV-positive, irrespective of geographical origin [41].
The EBV virus was classified as a group 1 carcinogenic
agent by the IARC.
HNSCC and human papillomavirus (HPV)
It is established that HPV types 16, 18, 31, and 45 play a
significant role in cervical cancer, as well as anal, vaginal,
and other anogenital cancers. Recent studies showed that
certain types of HPV are also closely related with malig-
nant growth of the epithelial mucosa lining in head and
neck areas. HPV-related tumours display clinical and
molecular characteristics that are distinct from HPV-
unrelated tumours such as those caused by alcohol con-
sumption and tobacco smoking. HPV-associated HNSCC
seems to have a better prognosis than HPV-negative
tumours due to increased sensitivity to chemoradiother-
apy. In particular, 90% of HPV-positive HNSCCs are posi-
tive for HPV type 16 [42], and the dominance of HPV
type 16 in HPV-positive HNSCC is even greater than that
seen in cervical carcinoma (50%-60%). The high-risk sub-
types of HPV involved in cervical carcinogenesis have
shown similar associations with HNSCC [43]. Moreover,
an increasing number of HPV-associated oropharyngeal
cancers has been noted during the last few decades world-
wide and has been linked to sexual behaviour [42].
Kaposi’s sarcoma and HIV/HHV-8
An association of HIV with head and neck cancers was
revealed back in the early 1980s along with the first clin-
ical observation of its association with symptoms such
as lymph node hyperplasias, candidiasis, herpes virus
infections, and neoplasias such as Kaposi’s sarcoma (KS)
or HIV-associated Non-Hodgkin’s lymphomas (HIV-NHL)
that were previously recognised as common ear, nose, and
throat (ENT) disorders [44]. The most common HIV-
associated malignancy is Kaposi’s sarcoma, accounting for
up to 80% of HIV-related cancers [45]. KS is normally a
rare type of cancer, but after HIV-1 infection its incidence
is greatly elevated, reaching a 70,000-fold increased inci-
dence in HIV-infected homosexual men [46]. The oral
cavity is the most common site of otolaryngological mani-
festations, and nearly 95% of lesions are found on the pal-
ate. Other sites include gingival surfaces of the oropharynx,
external ear, larynx, and nose [47]. Endemic KS and AIDS-
associated KS (AIDS-KS) tend to be more aggressive than
classical KS and AIDS-KS lesions often rapidly progress to
plaques and nodules affecting the upper trunk, face, and
oral mucosa.
Human herpes virus type 8 (HHV-8) [or Kaposi’s
sarcoma-associated herpes virus (KSHV)] was originally
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expressing candidate viral oncogenes that constitutively
activate growth-signalling pathways [49,50] and has sub-
sequently been shown to have a strong correlation with
different forms of KS. HHV-8 is predominantly found in
tumour spindle cells but has also been detected in lym-
phocytes, monocytes, and keratinocytes [49,51].
Oral squamous cell carcinoma (OSCC) and bacterial and
mycotic infections
There is an apparent link between some bacterial species
and certain forms of cancer. In addition to tobacco and
alcohol consumption, S. anginosus infection is a signifi-
cant risk factor for eosophageal and head and neck
cancer, precancerous leukoplakia, and squamous cell
carcinoma, although the exact mechanisms are unknown
[6,52,53]. One report [6] indicated positivity for S. angi-
nosus DNA in samples obtained from head and neck
cancers by PCR and Southern blot analyses (100% and
33% respectively). S. anginosus DNA was detected more
frequently in squamous cell carcinoma than other forms
of cancer and showed a correlation with aerodigestive
tract cancer [52,54].
Other bacterial pathogens such as Prevotella melanino-
genica, Eubacterium saburreum, C. gingivalis, Leptotrichia
buccalis, and Streptococcus mitis species demonstrated
higher levels of accumulation in OSCC patients than in
control groups [55]. It has been proposed that alteration
of tumour cell receptors could change the adhesion of
certain bacterial species [56].
Exiguobacterium oxidotolerans, P. melaninogenica,
Staphylococcus aureus, Veillonella parvula, and Micro-
coccus species were isolated from OSCC sites but not
from control sites, whereas Moraxella osloensis, P. vevor-
alis, and Acromyces were found only in control samples.
The majority of microorganisms isolated from tumours
were saccharolytic and acid-tolerant, such as yeasts, acti-
nomycetes, bifidobacteria, lactobacilli, streptococci, and
Veillonella, indicating an acidic and hypoxic tumour
microenvironment.
Fungal infections such as chronic hyperplastic candi-
dosis caused by Candida species showed association
with the invasion of candidal hyphae into oral epithe-
lium and progression to dysplasic changes [55].
Mechanisms of carcinogenesis
Mechanisms in brain cancers
Consensus was recently reached on the oncomodulatory
role of HCMV in gliomas when HCMV was shown to
interact with the key signalling pathways in cancer
development [57]. The mechanism of glioblastoma de-
velopment was recently elucidated by Bleeker et al., who
showed that many of the alterations involve PI3K/AKT, ret-
inoblastoma (Rb), and p53, signalling pathways downstreamof the tyrosine kinase receptor [58]. Interestingly, CMV-
infected cells also exhibit reduced p53 and Rb function.
CMV influences carcinogenesis not only by expression of
cell proliferation factors, but also by immunosuppression
[8]. CMV interleukin (IL)-10 was shown to convert mono-
cytes and microglia in glioblastomas to an immunosuppres-
sive phenotype that supports tumour development [18]. In
immunocompetent individuals CMV infection is asymp-
tomatic, but constant antigenic pressure leads to an in-
crease in CD8 +CD57+, CD4 +CD28-, and CD8 +CD28-
cells specific to CMV antigen pp65. These cells express
enkephalin-inhibiting receptors, thus blocking the functions
of cytotoxic lymphocytes [9]. In addition, analysis of CMV
proteins showed that US28 is a constitutively active chemo-
kine receptor that induces an oncogenic phenotype by in-
creasing the expression of COX-2, PGE2, and IL6 [59].
A characteristic feature of JCV infection is early activa-
tion of the human neurotropic viral promoter JCVE,
which initiates transcription of large T-antigen [60,61].
The major molecular mechanisms of polyomavirus
oncogenesis involve inhibition of tumour suppressors by
viral T-antigens and epigenetic transcriptional regulation
through histone acetylation. T-antigens of all papova-
viruses bind to Rb, leading to disruption of cell cycle
regulation. They also bind to and inactivate CBP/p300
and p53 proteins. Large T-antigen shows mutagenic po-
tential towards cellular DNA and prevents DNA repair.
Less is understood about the oncogenic properties of
small T-antigen, but it is known to play a mitogenic role
and is involved in cell transformation and uncontrolled cell
proliferation [9,61]. Other viral proteins (e.g., agnoprotein)
bind to p53 and increase the activity of p21/WAF-1 [62].
The effect of parasites on host immunity increases the
risk of brain cancer by triggering chronic inflammation,
inhibiting apoptosis, and through transfer of genetic ma-
terial from the parasite to the host [31]. For example, T.
gondii persists in human pseudocysts, macrophages, and
neurons. In the latent phase the parasite is in the brady-
zoite stage and causes mild inflammation as a result of
the host’s immune response [63]. However, dying cysts
probably cause intense inflammation. In the case of
Taenia solium [64] and Plasmodium [65], persistent
cysts trigger the mitogenic response of lymphocytes to
achieve immunosuppression. In addition, cysticerci of T.
solium initially stimulate the immune response to pro-
duce a protein source for the parasite and subsequently
acquire the host membrane proteins thus avoiding
immunodetection. Larvae of Schistosomula resemble na-
tive lymphocytes and evade the immune response [29].
Summing up, any interference with, or evasion of, the host
immune system may predispose an organism to cancer,
although much remains to be learned about the interac-
tions between parasites, the host immune response, and
brain cancer development.
Alibek et al. Infectious Agents and Cancer 2013, 8:7 Page 5 of 9
http://www.infectagentscancer.com/content/8/1/7Mechanisms in head and neck cancers
In EBV-associated carcinogenesis, the virus infects B
lymphocytes through binding of the major envelope
glycoprotein gp350 to the B cell CD21 receptor and
binding of a second glycoprotein, gp42, to MHC class II
molecules as a co-receptor [10]. The transformation of
EBV viral particles [Epstein-Barr nuclear antigens (EBNAs),
latent membrane proteins (LMPs) and Epstein-Barr virus-
encoded small RNA (EBERs)] from B cells into latently
infected lymphoblastoid cell lines, both in lytic and latent
cycles, ultimately affects host genome regulation causing
dysregulation of apoptosis, genetic instability, and constant
proliferation. It has also been suggested that EBV enters
nasopharyngeal cells through IgA-mediated endocytosis.
Because the EBV genome is monoclonal in nature, EBV
infection occurs before clonal expansion of the malignant
cells [10,41].
Recent studies showed that non-polyadenylated RNAs
(EBERs) are present in all infected cells. This supports
the idea that EBV infection is involved in an early stage
of NPC carcinogenesis [10]. Molecular abnormalities in
NPCs are complex and include inactivation of RASSF1A
and p16 tumour suppressor genes on 3p21 and 9p21
chromosomal regions by homologous deletion and pro-
moter methylation during low-grade dysplasia stages.
These events occur early in pathogenesis and might pre-
dispose the abnormal epithelium to subsequent infection
with EBV derived from adjacent lymphoid tissues and
circulating B-cells. Inactivation of TSCL1, EDNRB, and
death-associated protein kinase genes via promoter
methylation is also frequently observed. Gene expression
profiling showed dysregulation of PI3K/Akt, Wnt/β-
catenin, TGF-8, and mitogen-activated protein kinase
(MAPK) signalling pathways in NPC with upregulation
of NF-k82, survivin, and Bcl-2, nuclear accumulation of
β-catenin, and dysregulation of integrins [10]. Almost all
EBV genes are expressed in the active phase of infection.
The early genes BRLF1 and BZLF1, which code tran-
scriptional transactivator proteins that promote cell rep-
lication, induce expression of the viral genes. BZLF1 and
BRLF1 proteins also inhibit the tumour suppressors p53
and pRb, respectively [9].
HPV-related carcinogenesis involves integration of the
HPV DNA into the host cell and expression of the viral
oncoproteins E6 and E7. E6 protein induces degradation
of p53 through ubiquitin-mediated proteolysis, leading
to loss of p53 activity. E7 protein binds to pRb, inducing
S-phase entry and leading to proliferation, malignant
transformation, and cell-cycle dysregulation. E6 and E7
proteins can activate expression of somatic cell telo-
merases, inducing proliferation and cellular division. In
humans, 85% of malignant neoplasias show elevated
telomerase activity, compared with only 27% of benign
tumours. Telomerase activity in HPV-infected cellsdecreases the expression of pRb and p53 and increases
expression of p21WAF1 and p16INK4a in vitro. More-
over, p21WAF1 is inactivated, probably due to binding
of E7 protein. These alterations lead to loss of control of
the G2/M transition and result in accumulation of muta-
tions and instability of the affected cell’s genome [9].
The pathogenesis process of KS appears to be com-
plex, involving various mechanisms dependent on both
viral and cellular activities, and is related to inflamma-
tion and angiogenesis promoted by endothelial growth
factors (β-FGF, PDGF, VEGF) and HIV-Tat as well as cell
proliferation and anti-apoptotic activity through vBCL2
[49,66,67]. The role of HIV-1 infection in the initiation
and progression of AIDS-KS involves two crucial para-
crine mechanisms: production of the HIV Tat protein
and promotion of cytokine production [68]. HIV-1 Tat is
an 86-amino acid protein with the primary function of
increasing the processivity of RNA polymerase II and
transcription initiation [69,70]. In contrast, there is no
clear evidence for the role of HHV-8 in KS pathogenesis.
Based on current data, HHV-8 infection appears to be
necessary, but not sufficient, for the development of KS
and additional co-factors, such as hormones, genetic pre-
disposition, and/or co-infection with other infectious
agents, are probably required for disease development [71].
Several mechanisms have been proposed for bacterial
carcinogenesis. Studies have indicated that several bac-
teria can cause chronic infections by producing toxins
that interfere with the cell cycle and lead to changes in
cell growth [72-74]. Other chronic bacterial infections
induce cell proliferation via activation of MAPK path-
ways and cyclin D1 [75], and several infections can sup-
press apoptosis by modulation of Bcl-2 proteins or by
inactivation of pRb [76]. Also, many pathogenic bacteria
that cause chronic infection with intracellular access
destroy the host cell signalling pathways, thus enhancing
survival of the pathogen [77]. Regulation of these signal-
ling factors is essential for the development or inhibition
of carcinogenesis. Such infections can mimic some of
the major events in tumour development, and indeed
the precancerous lesions formed in such infections can
regress with antibiotic treatment and elimination of
bacteria.Concluding notes: Can carcinogenesis be inhibited by
treatment against infections?
Various studies have shown that anti-viral and anti-bacterial
drug treatments have a favourable effect on prognosis
through prevention of tumorigenesis. Thus, oncologists may
benefit from understanding the mechanisms of infection-
related carcinogenesis to develop novel cancer treatment
strategies. A summary of this information is presented in
Table 1.
Table 1 Cancer diseases and associated infectious agents
Type of tumour Infectious Agent Direct/indirect
carcinogenesis*
Mechanism of Carcinogenesis
Glioblastoma CMV indirect Interference with signaling pathways, reduced p53 and Rb function,
increasing level of telomerase, angiogenic factors, cell motility and invasion.
Chronic inflammation, expression of COX-2, PGE2, VEGF, IL-6 production,
STAT3 phosphorylation [8,58,59]
Medulloblastoma
Glioma JC direct Viruses express T-antigen and agnoprotein, which binds to tumour
supressors p53 and Rb, inactivate CBP/p300, increase the activity of p21/
WAF-1, prevents DNA repair; small T-antigen involved in cell transformation;






Glioma Toxoplasma gondii indirect Chronic inflammation, mutation accumulation, inhibit apoptosis; cysts
trigger the mitogenic response of lymphocytes to achieve
immunosuppression [63]Astrocytoma
Meningioma
Glioma Mycoplasma indirect Cytokine-mediated damage and inflammatory lesions [34-36]
CNS lymphoma EBV direct Transformation of B-cells [78]
Nasopharyngeal
carcinoma




HNSCC HPV direct Loss of p53 and pRb, activation of telomerase [9]
Kaposi’s Sarcoma HIV/HHV-8 direct Angiogenesis promoted by endothelial growth factors (β-FGF, PDGF, VEGF)
and HIV-Tat as well as cell proliferation and anti-apoptotic activity through
vBCL2 [49,66-71]HIV-NHL
Eosophageal cancer S. anginosus indirect Mechanism needs further investigation
HNSCC
OSCC
HNSCC Candida spp. indirect Similar ability to promote neoplastic changes as the known promoter
phorbol-12,13-didecanoate [79]
OSCC
*Agents Classified by the IARC Monographs, Volumes 1–106 [80].
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tion with HPV types 16 and 18 include Cervarix and
Gardasil, which have proved effective against cervical
cancer several years after vaccination [81]. As an ex-
ample of multivalent vaccine prevention, recent preclin-
ical studies show that vaccination against HPV 16, 18,
31, 45, and 52 subtypes targeting E7 proteins in mam-
mals (e.g., mice and Rhesus monkeys) result in anti-
tumour responses and reduction of the TC-1 tumour
cell population [82,83]. The recombinant protein-based
vaccine Pentarix elicits a CD8 response against five
strains of HPV in human. These findings suggest that
prevention of infection with HPV subtypes is crucial for
inhibiting tumour development in HPV-associated ma-
lignant neoplasia. Another study involving synthetic
vaccine against high-risk HPV type 16 demonstrated in-
duction of a potent T-cell response and complete regres-
sion of all lesions and eradication of virus in 9 of 20
women with high-grade vulvar intraepithelial neoplasia[84]. These therapeutic vaccines can therefore trigger a
sufficient immune response to target the pathogen and
suppress cancer development.
CMV is detectable in the majority of GBMs and could
be a potential target for treatment. Even low levels of
CMV gene expression can be used for immunologic
targeting [18]. Interestingly, T-cell therapy for patients
with CMV +GBMs was very beneficial and has entered
phase I/II clinical trials [85]. Such therapies expand
CMV-specific T-cell populations, which recognise pp65+
and IE1+ targets and kill CMV-infected autologous
GBM cells [85].
Similarly, in EBV-related nasopharyngeal carcinoma,
treatment of the infection produced promising outcomes
with respect to cancer prevention. Yoshizaki et al. [86]
demonstrated that treatment of EBV by injection of the
anti-viral drug cidoflovir into the tumour once every
3 weeks suppressed tumour growth, and analysis of EBV-
encoded RNA revealed reduction within the tumour cell
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meningitis, encephalitis, post-transplant lymphoprolifera-
tive disease (PTLD), and CNS lymphoma are associated
with EBV infection although antiviral therapy was either
ineffective [87] or successful [78,88] in such cases. Results
on clinical efficacy are therefore inconsistent. In another
study, co-administration of adjuvant interferon-beta after
radiochemotherapy for 17 squamous cell carcinomas and
nine undifferentiated carcinomas showed a 100% survival
rate at 96 months [44]. It is known that adjuvant
interferon-beta therapy in combination with a high dose-
hyperfractionated radiation increases the efficacy of in-
tensely modified radiation therapy.
Despite a vast number of reported cases, the role of in-
fectious agents in the mechanisms of carcinogenesis
demands further attention from clinicians. Statistically, it
appears that infections are associated with the vast ma-
jority of brain and head and neck cancers, and it there-
fore seems likely that such infections may at the very
least modulate cancer pathogenesis. However, it is un-
clear whether the infectious environment predisposes
the patient to carcinogenesis by down-regulating the
host immune system or whether cancer cells debilitate
the cellular and immune response so that the infectious
agents can easily overcome the defence mechanisms and
evade the host cells. Nevertheless, the effectiveness of
anti-virals, antibiotics, and therapeutic vaccines against
onco-associated infections in cancer treatment has been
reported in several studies. Based on the data reported
in this review, we believe that combating pathogens
could be a key treatment strategy to reduce or even pre-
vent brain and head and neck malignancies.
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